Assessing clonal changes in T cells over time following immunotherapy is a breeze with Cyclone

Anthony R Cillo; John M Kirkwood

doi:10.1016/j.ccell.2024.08.014

Assessing clonal changes in T cells over time following immunotherapy is a breeze with Cyclone

Cancer Cell. 2024 Sep 9;42(9):1491-1493. doi: 10.1016/j.ccell.2024.08.014.

Authors

Anthony R Cillo¹, John M Kirkwood²

Affiliations

¹ Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA; Tumor Microenvironment Center, UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA, USA; Cancer Immunology and Immunotherapy Program, UPMC Hillman Cancer Center, Pittsburgh, PA, USA.
² Department of Medicine, Division of Hematology/Oncology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA. Electronic address: [email protected].

PMID: 39255774
DOI: 10.1016/j.ccell.2024.08.014

Abstract

Combination immunotherapy improves outcomes in metastatic melanoma, but the underlying mechanisms remain unclear. In this issue of Cancer Cell, Wang et al.¹ report dynamics and transcriptional states of CD8⁺ T cell clones over time in patients treated with anti-PD-1, anti-CTLA-4, or a combination of the two. These findings have important implications for understanding and monitoring combination immunotherapy.

MeSH terms

CD8-Positive T-Lymphocytes* / drug effects
CD8-Positive T-Lymphocytes* / immunology
CTLA-4 Antigen / antagonists & inhibitors
CTLA-4 Antigen / immunology
Humans
Immunotherapy* / methods
Melanoma* / drug therapy
Melanoma* / immunology
Melanoma* / therapy
Programmed Cell Death 1 Receptor / antagonists & inhibitors
Programmed Cell Death 1 Receptor / immunology

Substances

CTLA-4 Antigen
Programmed Cell Death 1 Receptor